Emerging data and current challenges for young, old, obese, or male patients with breast cancer

Clinical Cancer Research

Volumn 23, Issue 11, 2017, Pages 2647-2654

  Freedman, Rachel A ^a   Partridge, Ann H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; GOSERELIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; FUNCTIONAL WELL BEING; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; LIFE EXPECTANCY; MALE; MALE BREAST CANCER; MASTECTOMY; MEDICAL CARE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MUTATIONAL ANALYSIS; NONHUMAN; OBESITY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSYCHOSOCIAL WELL BEING; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SUPPORTIVE CARE; SURVIVAL RATE; SURVIVAL TIME; THERAPEUTIC DECISION MAKING; TUMOR HETEROGENEITY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; WEIGHT GAIN; WELLBEING; YOUNG ADULT; ADJUVANT CHEMOTHERAPY; AGE; BREAST TUMOR; COMPLICATION; DECISION MAKING; FEMALE; PATHOLOGY; PROCEDURES; PROGNOSIS;

AGE FACTORS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; HUMANS; MALE; OBESITY; PROGNOSIS;

EID: 85020258075     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2552     Document Type: Article

References (98)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER) Cancer Statistics; 2016. Available from: https://seer.can cer.gov/statfacts/html/breast.html.
2. American Cancer Society. Cancer Treatment and Survivorship Facts and Figures 2016-2017; 2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatmentandsurvivorship-facts-and-figures/cancer-treatment-and-survivorship-factsandfigures-2016-2017.pdf.
3. Reeder-Hayes KE, Anderson BO. Breast cancer disparities at home and abroad: a review of the challenges and opportunities for system-level change. Clin Can Res 2017;23:2655-64.
4. Yates LR, Desmedt C. Translational genomics: practical applications of the genomic revolution in breast cancer. Clin Cancer Res 2017;23:2630-9.
5. Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Cancer Res 2017;23:2640-6.
6. Nik-Zainal S, Morganella S. Mutational signatures in breast cancer: the problem at the DNA level. Clin Cancer Res 2017;23:2617-29.
7. American Cancer Society. Breast Cancer Facts and Figures 2015-2016; 2016. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breastcancerfacts-and-figures-2015-2016.pdf.
8. Keegan TH, De Rouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012;14:R55.
9. Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 2016;34:3308-14.
10. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 2013;31:2692-8.
11. Azim HA Jr, Botteri E, Renne G, Dell'orto P, Rotmensz N, Gentilini O, et al. The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Acta Oncol 2012;51:653-61.
12. Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, et al. Postpartum diagnosisdemonstrates a high risk formetastasis andmerits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat 2013;138:549-59.
13. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006;6:281-91.
14. Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, Martinson HA, et al. Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Invest 2014;124:3901-12.
15. Borges VF, Elder AM, Lyons TR. Deciphering pro-lymphangiogenic programs during mammary involution and postpartum breast cancer. Front Oncol 2016;6:227.
16. Goddard G, Hill R, Nemkov T, D'Alessandro A, Hansen KC, Maller O, et al.: The rodent liver undergoes weaning-induced involution and supports breast cancer metastasis. Cancer Discov 2017;7:177-87.
17. Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, et al. Molecular phenotype of breast cancer according to time since last pregnancy in a large cohort of young women. Oncologist 2015;20:713-8.
18. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372:436-46.
19. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18.
20. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6.
21. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-8.
22. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in womenwith breast cancer. Breast Cancer Res Treat 2011;126:529-37.
23. Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. JNatlCancer Inst 2015;107. pii: djv202.
24. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 2014;312:902-14.
25. Pesce CE, Liederbach E, Czechura T, Winchester DJ, Yao K. Changing surgical trends in young patientswith early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. J Am Coll Surg 2014;219:19-28.
26. Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a crosssectional survey. Ann Intern Med 2013;159:373-81.
27. Rosenberg SM, Partridge AH. Contralateral prophylactic mastectomy: an opportunity for shared decision making. JAMA Surg 2014;149:589-90.
28. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features andmolecularphenotypebypatient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131:1061-6.
29. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG, et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer 2007;7:160.
30. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-65.
31. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the "Silver Tsunami": prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016;25:1029-36.
32. Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, et al. Agespecific changes in intrinsic breast cancer subtypes: a focus on older women. Oncologist 2014;19:1076-83.
33. Shak S, Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, et al. Breast cancer specific survival in 38, 568 patients with node negative hormone receptor positive invasive breast cancer and oncotype DX recurrence score results in the SEER database [abstract]. In: Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2015 Dec. 8-12; San Antonio, TX. Philadelphia (PA): AACR; 2016. Abstract nr P5-15-01.
34. Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS One 2016;11:e0165409.
35. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 2010;28:2038-45.
36. Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy EP. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011;29:1570-7.
37. Vaz Luis I, Lin NU, Keating NL, Barry WT, Winer EW, Freedman RA. Factors associated with early mortality in metastatic breast cancer: a populationbased study. Oncologist 2017;26:386-93.
38. Smith BD, Jiang J, McLaughlin SS, Hurria A, Smith GL, Giordano SH, et al. Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 2011;29:4647-53.
39. Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 2014;32:927-34.
40. Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, et al. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat 2016;159:151-62.
41. Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, et al. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 2014;145:491-501.
42. Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 2007;25:2522-7.
43. Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 2016;34:2003-9.
44. Field KM, Kosmider S, Jefford M, Michael M, Jennens R, Green M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008;4:108-13.
45. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, et al. Adjuvant chemotherapy in older and younger women with lymph nodepositive breast cancer. JAMA 2005;293:1073-81.
46. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006;24:2750-6.
47. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106. pii: dju055.
48. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-65.
49. Riley GF, Warren JL, Harlan LC, Blackwell SA. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 2011;1:E1-E26.
50. Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst 2015;107. pii: djv130.
51. Biggers A, Shi Y, Charlson J, Smith EC, Smallwood AJ, Nattinger AB, et al. Medicare D subsidies and racial disparities in persistence and adherence with hormonal therapy. J Clin Oncol 2016;34:4398-404.
52. Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 2014;32:2587-94.
53. Freedman RA, Foster JC, Seisler DK, Lafky J, Kimmick G, Jatoi A, et al. A151527: accrual of older breast cancer patients to alliance systemic therapy trials over time. J Clin Oncol 2017;35:421-31.
54. Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. J Clin Oncol 2015;33:3826-33.
55. Hurria A, Cohen HJ, Extermann M. Geriatric oncology research in the cooperative groups: a report of a SIOG Special Meeting. J Geriatr Oncol 2010;1:40-4.
56. Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA 2013;310:1795-6.
57. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifenwith orwithout irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-7.
58. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457-65.
59. Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011;29:1290-6.
60. Hurria A, Lichtman SM, Gardes J, Li D, Limaye S, Patil S, et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 2007;55:1604-8.
61. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012;118:3377-86.
62. eprognosis. Estimating prognosis for elders; 2016. Available from: http://eprognosis.ucsf.edu/.
63. National vital statistics reports, September 24, 2012. United States Life Tables; 2008. Vol 61, No 3 Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-03.pdf.
64. Wenzel JA, Griffith KA, Shang J, Thompson CB, Hedlin H, Stewart KJ, et al. Impact of a home-based walking intervention on outcomes of sleep quality, emotional distress, and fatigue in patients undergoing treatment for solid tumors. Oncologist 2013;18:476-84.
65. Griffith K, Wenzel J, Shang J, Thompson C, Stewart K, Mock V. Impact of a walking intervention on cardiorespiratory fitness, self-reported physical function, and pain in patients undergoing treatment for solid tumors. Cancer 2009;115:4874-84.
66. Geraedts H, Zijlstra A, Bulstra SK, Stevens M, Zijlstra W. Effects of remote feedback in home-based physical activity interventions for older adults: a systematic review. Patient Educ Couns 2013;91:14-24.
67. Nyrop KA, Muss HB, Hackney B, Cleveland R, Altpeter M, Callahan LF. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy. J Geriatr Oncol 2014;5:148-55.
68. Campo RA, O'Connor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, et al. Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integr Cancer Ther 2013;12:464-74.
69. Cancer Statistics Center. American Cancer Society. Available from https://cancerstatisticscenter.cancer.org/?-ga=1.214017811.52651240.1479931067#/cancer-site/Breast.
70. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811-4.
71. Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst 2014;106:djt465.
72. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2016;18:15.
73. Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge GW. Molecular characterization of male breast cancer by standardized quantitative RTPCR analysis: first large genomic study of 347 male breast cancers compared to 82, 434 female breast cancers. J Clin Oncol 27:15s, 2009 (suppl; abstr 549).
74. Massarweh SA, Choi GL. Special considerations in the evaluation and management of breast cancer in men. Curr Probl Cancer 2016;40:163-71.
75. Farrell E, Borstelmann N, Meyer F, Partridge A, Winer E, Ruddy K. Male breast cancer networking and telephone support group: a model for supporting a unique population. Psychooncology 2014;23:956-8.
76. Male breast cancer coalition. Available from http://malebreastcancercoalition.org/.
77. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 2003;348:1625-38.
78. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One 2012;7:e51446.
79. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:307-14.
80. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in womenwith breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014;25:1901-14.
81. Protani M, Coory M, Martin JH. Effect of obesity on survival ofwomenwith breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-35.
82. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a metaanalysis. Int J Cancer 2009;124:698-712.
83. Nechuta S, Chen WY, Cai H, Poole EM, Kwan ML, Flatt SW, et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogenreceptorpositive breast cancer prognosis. Int J Cancer 2016;138:2088-97.
84. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010;28:3411-5.
85. Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015;150:127-39.
86. Widschwendter P, Friedl TW, Schwentner L, DeGregorio N, Jaeger B, Schramm A, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015;17:129.
87. Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM. Overweight as a prognostic factor for triple-negative breast cancers in Chinese women. PLoS One 2015;10:e0129741.
88. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptorpositive operable breast cancer. Cancer 2012;118:5937-46.
89. Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, et al. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer 2013;49:3588-97.
90. Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 2013;119:2447-54.
91. Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 2016;34:4203-16.
92. Pfeiler G, Konigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011;29:2653-9.
93. American Society of Clinical Oncology. Obesity and cancer; 2016. Available from: http://www.asco.org/practice-guidelines/cancer-care-initiatives/prevention-survivorship/obesity-cancer.
94. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol 2014;32:3568-74.
95. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012;30:1553-61.
96. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol 2015;1:611-21.
97. Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol 2014;32:2231-9.
98. Ligibel JA, Meyerhardt J, Pierce JP, Najita J, Shockro L, Campbell N, et al. Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting. Breast Cancer Res Treat 2012;132:205-13.